PMCB vs. SNTI, AIM, APTO, EVAX, TVGN, ZIVO, COEP, CHRO, GENE, and BCDA
Should you be buying PharmaCyte Biotech stock or one of its competitors? The main competitors of PharmaCyte Biotech include Senti Biosciences (SNTI), AIM ImmunoTech (AIM), Aptose Biosciences (APTO), Evaxion Biotech A/S (EVAX), Tevogen Bio (TVGN), ZIVO Bioscience (ZIVO), Coeptis Therapeutics (COEP), Chromocell Therapeutics (CHRO), Genetic Technologies (GENE), and BioCardia (BCDA). These companies are all part of the "biological products, except diagnostic" industry.
PharmaCyte Biotech (NASDAQ:PMCB) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, community ranking, dividends, valuation, earnings and profitability.
Senti Biosciences has a consensus target price of $6.00, indicating a potential upside of 1,470.68%. Given Senti Biosciences' higher possible upside, analysts plainly believe Senti Biosciences is more favorable than PharmaCyte Biotech.
PharmaCyte Biotech has higher earnings, but lower revenue than Senti Biosciences. PharmaCyte Biotech is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Senti Biosciences had 1 more articles in the media than PharmaCyte Biotech. MarketBeat recorded 1 mentions for Senti Biosciences and 0 mentions for PharmaCyte Biotech. PharmaCyte Biotech's average media sentiment score of 0.00 equaled Senti Biosciences'average media sentiment score.
Senti Biosciences received 3 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users.
34.2% of PharmaCyte Biotech shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 1.0% of PharmaCyte Biotech shares are held by insiders. Comparatively, 12.5% of Senti Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
PharmaCyte Biotech has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.88, meaning that its share price is 188% more volatile than the S&P 500.
PharmaCyte Biotech has a net margin of 0.00% compared to Senti Biosciences' net margin of -2,692.82%. PharmaCyte Biotech's return on equity of -9.69% beat Senti Biosciences' return on equity.
Summary
Senti Biosciences beats PharmaCyte Biotech on 8 of the 14 factors compared between the two stocks.
Get PharmaCyte Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PMCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PharmaCyte Biotech Competitors List
Related Companies and Tools
